LU85081A1 - Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire - Google Patents

Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire Download PDF

Info

Publication number: LU85081A1
Authority: LU; Luxembourg
Prior art keywords: keratin; skin; polymer; composition; composition according
Prior art date: 1983-11-09

Application number

LU85081A

Other languages

English (en)

French (fr)

Inventor

Brod Joel

Kermici Michel

Original Assignee

Oreal

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-11-09

Filing date

1983-11-09

Publication date

1985-07-17

1983-11-09 Application filed by Oreal filed Critical Oreal

1983-11-09 Priority to LU85081A priority Critical patent/LU85081A1/fr

1984-11-07 Priority to PCT/FR1984/000253 priority patent/WO1985002120A1/fr

1984-11-07 Priority to EP84402242A priority patent/EP0147261B1/de

1984-11-07 Priority to DE8484402242T priority patent/DE3482754D1/de

1984-11-07 Priority to JP59504078A priority patent/JPS61500359A/ja

1984-11-08 Priority to CA000467386A priority patent/CA1244762A/fr

1985-07-17 Publication of LU85081A1 publication Critical patent/LU85081A1/fr

1987-09-14 Priority to US07/095,897 priority patent/US4959213A/en

Links

239000000203 mixture Substances 0.000 title claims description 32
239000003814 drug Substances 0.000 title claims description 18
238000011282 treatment Methods 0.000 title claims description 14
230000004054 inflammatory process Effects 0.000 title claims description 12
208000017520 skin disease Diseases 0.000 title claims description 9
229940079593 drug Drugs 0.000 title claims description 8
230000002265 prevention Effects 0.000 title claims description 5
102000011782 Keratins Human genes 0.000 claims description 76
108010076876 Keratins Proteins 0.000 claims description 76
150000002632 lipids Chemical class 0.000 claims description 51
229920000642 polymer Polymers 0.000 claims description 30
206010015150 Erythema Diseases 0.000 claims description 15
231100000321 erythema Toxicity 0.000 claims description 14
239000002994 raw material Substances 0.000 claims description 13
241001465754 Metazoa Species 0.000 claims description 11
239000002904 solvent Substances 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 7
230000001681 protective effect Effects 0.000 claims description 7
230000000699 topical effect Effects 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
239000004202 carbamide Substances 0.000 claims description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
230000003647 oxidation Effects 0.000 claims description 5
238000007254 oxidation reaction Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
239000000839 emulsion Substances 0.000 claims description 4
230000008961 swelling Effects 0.000 claims description 4
230000007062 hydrolysis Effects 0.000 claims description 3
238000006460 hydrolysis reaction Methods 0.000 claims description 3
230000001737 promoting effect Effects 0.000 claims description 3
241000283690 Bos taurus Species 0.000 claims description 2
241000143973 Libytheinae Species 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
230000000536 complexating effect Effects 0.000 claims description 2
210000003746 feather Anatomy 0.000 claims description 2
210000000003 hoof Anatomy 0.000 claims description 2
230000035515 penetration Effects 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
230000003449 preventive effect Effects 0.000 claims description 2
210000004894 snout Anatomy 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
239000002562 thickening agent Substances 0.000 claims description 2
241000928106 Alain Species 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 33
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 33
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 33
229940031439 squalene Drugs 0.000 description 33
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 33
210000003491 skin Anatomy 0.000 description 31
GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 19
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
238000011068 loading method Methods 0.000 description 11
238000000034 method Methods 0.000 description 10
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
239000000243 solution Substances 0.000 description 8
206010000496 acne Diseases 0.000 description 7
239000000872 buffer Substances 0.000 description 7
239000000047 product Substances 0.000 description 6
230000005855 radiation Effects 0.000 description 6
230000015961 delipidation Effects 0.000 description 5
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
235000020778 linoleic acid Nutrition 0.000 description 5
239000000463 material Substances 0.000 description 5
150000002978 peroxides Chemical class 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000003756 stirring Methods 0.000 description 5
208000002874 Acne Vulgaris Diseases 0.000 description 4
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
-1 PEROXIDE LIPIDS Chemical class 0.000 description 4
206010041303 Solar dermatitis Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000000605 extraction Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
210000000434 stratum corneum Anatomy 0.000 description 4
239000000126 substance Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
229960000541 cetyl alcohol Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N n-octadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
238000005502 peroxidation Methods 0.000 description 2
235000015277 pork Nutrition 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229910052724 xenon Inorganic materials 0.000 description 2
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
HONMCSLFRKBQHG-UHFFFAOYSA-N 1,3-diamino-1,3-diphenylurea Chemical compound C=1C=CC=CC=1N(N)C(=O)N(N)C1=CC=CC=C1 HONMCSLFRKBQHG-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
QYIMSPSDBYKPPY-BANQPHDMSA-N 2,3-epoxysqualene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CCC1OC1(C)C QYIMSPSDBYKPPY-BANQPHDMSA-N 0.000 description 1
206010000349 Acanthosis Diseases 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
206010053177 Epidermolysis Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
102000005705 Keratin-5 Human genes 0.000 description 1
108010070553 Keratin-5 Proteins 0.000 description 1
244000025272 Persea americana Species 0.000 description 1
235000008673 Persea americana Nutrition 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
230000001914 calming effect Effects 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000004568 cement Substances 0.000 description 1
239000002801 charged material Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000036074 healthy skin Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
210000004020 intracellular membrane Anatomy 0.000 description 1
229960004232 linoleic acid Drugs 0.000 description 1
230000003859 lipid peroxidation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000013178 mathematical model Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000005086 pumping Methods 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007790 scraping Methods 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
230000028327 secretion Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
WRCITXQNXAIKLR-UHFFFAOYSA-N tiadenol Chemical compound OCCSCCCCCCCCCCSCCO WRCITXQNXAIKLR-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4741—Keratin; Cytokeratin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/842—Skin; hair; nails; sebaceous glands; cerumen

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Birds (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

LU85081A 1983-11-09 1983-11-09 Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire LU85081A1 (fr)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
LU85081A LU85081A1 (fr)	1983-11-09	1983-11-09	Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire
PCT/FR1984/000253 WO1985002120A1 (fr)	1983-11-09	1984-11-07	Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire
EP84402242A EP0147261B1 (de)	1983-11-09	1984-11-07	Medikament und medikamentöse Zusammensetzung zur Behandlung und/oder Verhinderung von Hautkrankheiten, verursacht durch eine Entzündung
DE8484402242T DE3482754D1 (de)	1983-11-09	1984-11-07	Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
JP59504078A JPS61500359A (ja)	1983-11-09	1984-11-07	炎症過程を伴う皮膚疾患の治療および（または）予防用薬剤および薬剤組成物
CA000467386A CA1244762A (fr)	1983-11-09	1984-11-08	Composition pharmaceutique pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire
US07/095,897 US4959213A (en)	1983-11-09	1987-09-14	Pharmaceutical composition for treatment and/or prevention of diseases of the skin involving an inflammatory process

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
LU85081		1983-11-09
LU85081A LU85081A1 (fr)	1983-11-09	1983-11-09	Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire

Publications (1)

Publication Number	Publication Date
LU85081A1 true LU85081A1 (fr)	1985-07-17

Family

ID=19730169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85081A LU85081A1 (fr)	1983-11-09	1983-11-09	Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire

Country Status (7)

Country	Link
US (1)	US4959213A (de)
EP (1)	EP0147261B1 (de)
JP (1)	JPS61500359A (de)
CA (1)	CA1244762A (de)
DE (1)	DE3482754D1 (de)
LU (1)	LU85081A1 (de)
WO (1)	WO1985002120A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5358935A (en) *	1992-11-19	1994-10-25	Robert Allen Smith	Nonantigenic keratinous protein material
US5932552A (en) *	1997-11-26	1999-08-03	Keraplast Technologies Ltd.	Keratin-based hydrogel for biomedical applications and method of production
US6270791B1 (en)	1999-06-11	2001-08-07	Keraplast Technologies, Ltd.	Soluble keratin peptide
US6371984B1 (en) *	1999-09-13	2002-04-16	Keraplast Technologies, Ltd.	Implantable prosthetic or tissue expanding device
US6270793B1 (en)	1999-09-13	2001-08-07	Keraplast Technologies, Ltd.	Absorbent keratin wound dressing
US6783546B2 (en)	1999-09-13	2004-08-31	Keraplast Technologies, Ltd.	Implantable prosthetic or tissue expanding device
US6461628B1 (en)	1999-09-13	2002-10-08	Keraplast Technologies, Ltd.	Non-woven keratin cell scaffold
US6316598B1 (en)	1999-09-13	2001-11-13	Keraplast Technologies, Ltd.	Water absorbent keratin and gel formed therefrom
US6544548B1 (en) *	1999-09-13	2003-04-08	Keraplast Technologies, Ltd.	Keratin-based powders and hydrogel for pharmaceutical applications
WO2003035722A1 (en) *	2001-09-25	2003-05-01	Southwest Research Institute	Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same
EP1478328B1 (de) *	2002-01-28	2013-06-05	Keraplast Technologies Ltd.	Bioaktive keratinpeptide
US7001987B2 (en)	2002-04-22	2006-02-21	Keraplast Technologies, Ltd.	Hydrogel with controllable mechanical, chemical, and biological properties and method for making same
US6914126B2 (en) *	2002-04-10	2005-07-05	Keraplast Technologies, Ltd.	Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks
US6989437B2 (en) *	2002-04-10	2006-01-24	Keraplast Technologies, Ltd.	Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks
US20040082717A1 (en) *	2002-06-24	2004-04-29	Southwest Research Institute	Keratin-silicone copolymers and interpenetrating networks (IPN's), methods of production and methods of use thereof
WO2007001339A2 (en)	2004-08-17	2007-01-04	Wake Forest University Health Sciences	Ambient stored blood plasma expanders
US8920827B2 (en) *	2005-10-21	2014-12-30	Wake Forest University Health Sciences	Keratin bioceramic compositions
EP1991253B1 (de)	2006-02-10	2013-07-31	Wake Forest University Health Sciences	Nervenregenerierung mit keratinbiomaterial
JP2009527274A (ja)	2006-02-17	2009-07-30	ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ	ケラチン医用生体材料から形成されるコーティングおよび生体用インプラント
US8273702B2 (en) *	2006-02-17	2012-09-25	Wake Forest University Health Sciences	Wound healing compositions containing keratin biomaterials
US7252816B1 (en)	2006-03-29	2007-08-07	Dow Pharmaceutical Sciences	Topical acne vulgairs medication with a sunscreen
US8604901B2 (en) *	2006-06-27	2013-12-10	Eyelock, Inc.	Ensuring the provenance of passengers at a transportation facility
BRPI0705059B1 (pt) *	2007-06-28	2016-05-31	Univ Rio De Janeiro	hidrolisados de queratina, processo para sua produção e composições cosméticas contendo os mesmos
US20090041686A1 (en) *	2007-08-06	2009-02-12	Osborne David W	Topical acne vulgaris composition with a sunscreen
US20090047260A1 (en) *	2007-08-17	2009-02-19	Wake Forest University Health Sciences	Keratin biomaterials for cell culture and methods of use
WO2010093882A1 (en)	2009-02-13	2010-08-19	Wake Forest University Health Sciences	Keratin biomaterials for cell culture and methods of use
JP2012526845A (ja)	2009-05-13	2012-11-01	ケラプラストテクノロジーズ，リミテッド	バイオポリマー材料
WO2011109808A1 (en) *	2010-03-05	2011-09-09	Wake Forest University Health Sciences	Controlled delivery system
WO2011112575A1 (en) *	2010-03-08	2011-09-15	Wake Forest University Health Sciences	Keratin biomaterials for treatment of ischemia
EP2640408B1 (de)	2010-11-17	2016-05-25	Wake Forest University Health Sciences	Keratinzusammensetzungen zur behandlung von knochenmangel oder -verletzungen
CN112724229B (zh)	2019-10-28	2023-09-26	中国医学科学院药物研究所	一种角蛋白bd-4、制法和其药物组合物与用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH188317A (de) *	1936-02-24	1936-12-31	A Wuelfing Johann	Verfahren zur Herstellung eines schwefelreichen, wasserlöslichen Gemisches von höhermolekularen Keratinabbauprodukten.
US3033755A (en) *	1961-04-14	1962-05-08	Kolmar Laboratories	Process for removing the water soluble materials from a keratin structure and cosmetic or pharmaceutical product formed therefrom
US3660566A (en) *	1969-06-12	1972-05-02	Lever Brothers Ltd	Extraction of lipid and cellular fractions from the stratum corneum of animal skin
JPS603104B2 (ja) *	1977-03-07	1985-01-25	積水化学工業株式会社	改良されたケラチン含有物質の製造方法
DE3014123C2 (de) *	1980-04-12	1982-03-18	B. Braun Melsungen Ag, 3508 Melsungen	Verfahren zur Herstellung von Skleroproteintransplantaten mit erhöhter biologischer Stabilität

1983
- 1983-11-09 LU LU85081A patent/LU85081A1/fr unknown
1984
- 1984-11-07 DE DE8484402242T patent/DE3482754D1/de not_active Expired - Lifetime
- 1984-11-07 JP JP59504078A patent/JPS61500359A/ja active Pending
- 1984-11-07 EP EP84402242A patent/EP0147261B1/de not_active Expired - Lifetime
- 1984-11-07 WO PCT/FR1984/000253 patent/WO1985002120A1/fr not_active Ceased
- 1984-11-08 CA CA000467386A patent/CA1244762A/fr not_active Expired
1987
- 1987-09-14 US US07/095,897 patent/US4959213A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1985002120A1 (fr)	1985-05-23
CA1244762A (fr)	1988-11-15
JPS61500359A (ja)	1986-03-06
EP0147261A2 (de)	1985-07-03
DE3482754D1 (de)	1990-08-23
EP0147261A3 (en)	1985-08-07
EP0147261B1 (de)	1990-07-18
US4959213A (en)	1990-09-25

Publication	Publication Date	Title
LU85081A1 (fr)	1985-07-17	Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire
EP0586392B1 (de)	1995-05-24	Verfahren zur trennung eines pflanzlichen präparates
EP1283708A2 (de)	2003-02-19	Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
CH676325A5 (de)	1991-01-15
CA2269895C (fr)	2011-01-18	Utilisation d'un extrait flavonoidique de ginkgo biloba substantiellement depourvu de terpenes, dans le domaine bucco-dentaire, et composition contenant un tel extrait
EP2254551B1 (de)	2013-11-06	Sterilisiertes Sucralfatgel
EP0117962A1 (de)	1984-09-12	Verfahren zur Herstellung von peroxydierten Fetten durch biologische Umsetzung mit niedriger Energie, mittels dieses Verfahrens erhaltene Produkte, Mischungen dieser Produkte mit Additiven und diese Produkte enthaltende Arzneimittel
FR2503561A1 (fr)	1982-10-15	Film flexible continu a usage cosmetique et pharmaceutique contenant des polypeptides
OA11026A (fr)	2003-03-10	Gel antimycosique à forte libération de substance active
FR2741266A1 (fr)	1997-05-23	Stimulation du metabolisme cellulaire par une proteine fixant reversiblement l'oxygene, celle-ci permettant la potentialisation de l'activite d'autres substances a vocation therapeutique ou cosmetique
EP0308456B1 (de)	1991-12-04	Zusammensetzung für die behandlung der epidermis
WO2014184340A1 (fr)	2014-11-20	Composition d'extraits d'ilex aquifolium et son utilisation
FR2613617A1 (fr)	1988-10-14	Agents medicamenteux pour la prevention et la therapie des brulures cutanees par rayons, contenant comme principe actif la 2,6-dimethyl-3,5-diethoxycarbonyl-1,4-dihydropyridine
FR2635459A1 (fr)	1990-02-23	Procede de fabrication de microspheres par reticulation de proteines, microspheres ainsi obtenues et leurs utilisations
EP0228978A1 (de)	1987-07-15	Zusammensetzungen zur therapeutischen Verwendung mit Gehalt an Organo-Silicium-Verbindungen
EP0099780B1 (de)	1989-09-06	Derivat von Keratin, Verfahren zu dessen Herstellung und dieses enthaltende Behandlungszusammensetzung
CA2493074A1 (fr)	2004-02-05	Elevation du taux d'heme oxygenase avec des derives de la rheine
WO1999063964A1 (fr)	1999-12-16	Procede de preparation de fibrilline a partir de cnidaires, et compositions obtenues utilisables en cosmetiques
BE856652A (fr)	1977-10-31	Composition pharmaceutique pour le traitement des troubles du sommeil
BE886485A (fr)	1981-04-01	Composition d'acide 2-(3-benzoylphenyl)-propionique (ketoprofene, dci) micro-encapsule pour usage therapeutique oral a action prolongee
FR2555051A1 (fr)	1985-05-24	Nouveau medicament constitue d'une huile peroxydee obtenue par transformation biologique a faible energie
EP2678024A1 (de)	2014-01-01	Kutane pharmazeutische zusammensetzungen zur topischen behandlung von atopischer dermatitis des hundes
FR2648351A1 (fr)	1990-12-21	Utilisation de complexes glycoproteiques extraits de bacteries gram(-) pour la fabrication d'un medicament facilitant la cicatrisation de la peau et procede de preparation
BE623473A (de)